Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance program — HUSKY Health, which includes Medicaid and CHIP enrollees — and it could ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Just a day after the S&P 500 and Nasdaq climbed into record territory, U.S. stocks end mixed, with American Express (AXP) and 3M (MMM) dragging the Dow, and more tariff drama muting markets.

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...